111 related articles for article (PubMed ID: 11983350)
1. Analytical performance of the Roche total and free PSA assays on the Elecsys 2010 immunoanalyzer.
Butch AW; Crary D; Yee M
Clin Biochem; 2002 Mar; 35(2):143-5. PubMed ID: 11983350
[No Abstract] [Full Text] [Related]
2. Evaluation of the analytical performance of the Boehringer Mannheim Elecsys 2010 immunoanalyzer.
Forest JC; Massé J; Lane A
Clin Biochem; 1998 Mar; 31(2):81-8. PubMed ID: 9622770
[TBL] [Abstract][Full Text] [Related]
3. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.
Gray MA; Cooke RR; Weinstein P; Nacey JN
Ann Clin Biochem; 2004 May; 41(Pt 3):207-12. PubMed ID: 15117434
[TBL] [Abstract][Full Text] [Related]
4. Automated Cobas Core PSA assays: sensitive, precise, and specific measurement of PSA-total and PSA-total/PSA-free ratio.
Groche D; Trebo R; Peters I; Pfleiderer P
Anticancer Res; 1999; 19(4A):2767-70. PubMed ID: 10470238
[TBL] [Abstract][Full Text] [Related]
5. Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening SA
Clin Chem; 1996 Jul; 42(7):1026-33. PubMed ID: 8674185
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems.
Haese A; Dworschack RT; Piccoli SP; Sokoll LJ; Partin AW; Chan DW
Clin Chem; 2002 Jun; 48(6 Pt 1):944-7. PubMed ID: 12029015
[No Abstract] [Full Text] [Related]
7. New developments in the standardization of total prostate-specific antigen.
Blijenberg BG; Storm BN; Van Zelst BD; Kruger AE; Schröder FH
Clin Biochem; 1999 Nov; 32(8):627-34. PubMed ID: 10638945
[TBL] [Abstract][Full Text] [Related]
8. Liaison free PSA--an automated chemiluminescent immunoassay for the determination of free prostate specific antigen (fPSA).
König B; Ivankovic B; Schleff R; Mack M
Anticancer Res; 1999; 19(4A):2763-5. PubMed ID: 10470237
[TBL] [Abstract][Full Text] [Related]
9. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
10. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
[TBL] [Abstract][Full Text] [Related]
11. Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance.
Laffin RJ; Chan DW; Tanasijevic MJ; Fischer GA; Markus W; Miller J; Matarrese P; Sokoll LJ; Bruzek DJ; Eneman J; Nelson J; Bray KR; Huang J; Loveland KG
Clin Chem; 2001 Jan; 47(1):129-32. PubMed ID: 11148190
[No Abstract] [Full Text] [Related]
12. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
[TBL] [Abstract][Full Text] [Related]
13. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer.
Schambeck CM; Schmeller N; Stieber P; Jansen HM; Pahl H; Schneider W; Fateh-Moghadam A
Urology; 1995 Aug; 46(2):195-9. PubMed ID: 7542821
[TBL] [Abstract][Full Text] [Related]
14. Disagreement between the Roche Cobas Core and Hybritech TANDEM-E PSA assays when measuring free, complexed and total serum prostate specific antigen.
Tillyer CR; Konings M; Gobin PT; Iqbal J
Ann Clin Biochem; 1994 Sep; 31 ( Pt 5)():501-5. PubMed ID: 7530440
[TBL] [Abstract][Full Text] [Related]
15. Ultrasensitive prostate-specific antigen assays and their clinical application.
Diamandis EP; Yu H; Melegos DN
Clin Chem; 1996 Jun; 42(6 Pt 1):853-7. PubMed ID: 8665675
[No Abstract] [Full Text] [Related]
16. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson RA; Yu H; Kalyvas M; Zammit S; Diamandis EP
Clin Chem; 1996 May; 42(5):675-84. PubMed ID: 8653891
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
19. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.
Jung K; Lein M; Brux B; Sinha P; Schnorr D; Loening SA
Clin Chem Lab Med; 2000 Dec; 38(12):1271-5. PubMed ID: 11205692
[TBL] [Abstract][Full Text] [Related]
20. Discordant prostate specific antigen test results despite WHO assay standardization.
Boegemann M; Arsov C; Hadaschik B; Herkommer K; Imkamp F; Nofer JR; Gerß J; Albers P; Semjonow A
Int J Biol Markers; 2018 Aug; 33(3):275-282. PubMed ID: 29734838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
